Xiaolin Wang

机构：National Institutes of Health, National Institute of Allergy and Infectious Diseases · ORCID：0000-0003-2280-7828

发表论文 21 篇 · 总被引 1258 次 · h-index 12

代表论文

• Altered Lipid Metabolism in Recovered SARS Patients Twelve Years after Infection (2017 · Scientific Reports · 被引 454)
• Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients (2020 · Cell Host & Microbe · 被引 306)
• Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (2019 · The Lancet · 被引 128)
• Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial (2022 · Nature Medicine · 被引 96)
• Cholesterol Metabolism—Impacts on SARS-CoV-2 Infection Prognosis (2020 · medRxiv · 被引 46)
• Clinical evidence of an interferon–glucocorticoid therapeutic synergy in COVID-19 (2021 · Signal Transduction and Targeted Therapy · 被引 39)